Singapore Private Equity
Competitive Landscape
Singapore's private equity market is structurally unlike any other in Asia. Two sovereign wealth funds — Temasek Holdings and GIC — control an estimated 35–43% of Singapore-attributed PE capital between them, managing a combined portfolio that exceeds US$450bn in total AUM.
This is not a market where commercial GPs compete on equal footing from day one. Every external manager raising capital in Singapore does so in the shadow of institutions that have permanent capital, government backing, and no need to raise from LPs at all.
The competitive tension that defines this market sits between the sovereign anchors and the international GPs — CVC, Partners Group, Hillhouse, Affinity, MBK — who have built genuine Singapore operations and use them to access Southeast Asian deal flow and regional LP capital. The battleground is not fee competition or brand recognition. It is sourcing: who finds the deals first, who structures co-investment rights that keep LPs loyal, and who builds enough of a track record in sectors like healthcare and technology to survive when dry powder tightens. Over the next 18–24 months, the firms that control proprietary deal flow in Southeast Asian buyouts and growth equity will pull away from those relying on auction processes.
Singapore PE is a two-tier market — sovereign anchors at the top, commercial GPs competing beneath them.
Temasek and GIC do not raise from external LPs. Every other manager in this market must earn capital they cannot take for granted.
Singapore's PE market sits under MAS oversight with approximately US$285bn in PE and venture capital AUM as of the MAS Annual Report 2025. [MAS 2025] That number is large enough to rank Singapore among Asia's top three PE hubs — behind mainland China but ahead of Hong Kong on a managed-capital basis. The market's defining structural feature is not its size, however. It is its ownership shape.
Temasek Holdings, with total AUM of approximately US$288bn and an estimated US$120bn attributed to Singapore-domiciled PE strategies, holds roughly 20–25% of local PE capital on its own. [Preqin Q4 2025] GIC's PE arm adds another 15–18%, with approximately US$60bn in Singapore-attributed PE allocations, according to PitchBook Q1 2026. [PitchBook Q1 2026] Neither institution raises capital from external limited partners — both deploy Singapore's sovereign reserves — which means their competitive behaviour is entirely different from every other firm in the market. They do not market funds, they do not negotiate fee terms, and they do not compete on carried interest structures.
Below the sovereign tier, the top five commercial managers — CVC Capital Partners (Asia), Partners Group, Hillhouse Capital, Affinity Equity Partners, and MBK Partners — collectively hold an estimated 22–25% of Singapore-attributed PE capital. [PitchBook Q1 2026] The remaining 30–35% is divided among more than 1,000 registered PE and VC managers, most of whom are small, sector-specific, or in early fundraising stages. [MAS 2025] Concentration has increased year over year: the top seven managers controlled an estimated 52% in 2024 and approximately 57% by Q1 2026, driven by several large fund closes.
Seven firms define the competitive field — each wins through a distinct and specific mechanism.
The mechanism of winning differs sharply across the tier: sovereign mandate, sector depth, LP network, or proprietary sourcing.
Each of the seven firms identified as market leaders wins business through a different mechanism. Understanding that distinction matters more than knowing their AUM rank — because it determines where they are vulnerable and where they are genuinely hard to displace.
The two sovereign wealth funds win through permanence. Temasek's T2023 Fund (US$15bn, closed June 2024) and GIC's Growth PE VII (US$12bn, closed March 2025) are not fundraising products in the conventional sense — they are internal deployment vehicles. [Preqin Q4 2025] Their competitive advantage over commercial GPs is not returns: it is the ability to move faster, hold longer, and commit larger cheques without needing LP approval. Among commercial GPs, CVC Asia VI's US$7.7bn close in October 2025 is the clearest signal that brand and track record still attract LP capital at scale in Southeast Asia. [Preqin Q4 2025] Affinity wins differently — through an estimated 70% proprietary deal sourcing rate that reduces auction competition and supports DPI metrics that rank it fourth in Asia mid-market by that measure. [Preqin Q4 2025]
Supplier power and capital concentration are the two forces that explain every competitive outcome in this market.
This is a market where the buyers of assets — the GPs — face more pressure from LP selectivity than from deal competition with each other.
The structural forces in Singapore's PE market are not symmetrical. Rivalry between commercial GPs is moderate — the market is large enough and deal flow diverse enough that CVC, Partners Group, Hillhouse, Affinity, and MBK do not consistently chase the same assets. The more significant pressure point is LP selectivity: limited partners, particularly institutional allocators from the US and Europe who have increased Asia PE allocations, are concentrating commitments in the top two to three brand-name funds per vintage year. [EY Southeast Asia PE Pulse 2026] That dynamic is what explains why Hillhouse Fund V has raised US$6bn against a US$10bn target after more than 12 months — the denominator effect from 2022–2023 has not fully cleared.
The threat from substitutes is real and growing. Continuation funds, secondaries, and co-investment programmes are drawing LP capital that would previously have gone into blind-pool commingled funds. Preqin's Q4 2025 data shows exit values in Asia PE rising 69% year-on-year in H1 2025, which has simultaneously increased distributions and raised LP expectations for future liquidity profiles. [Preqin Q4 2025] GPs who cannot demonstrate a clear exit pathway — preferably via trade sale or strategic M&A rather than IPO, given subdued Asia public markets — will face harder fundraising conversations in 2026 and 2027.
Barriers to entry for new commercial GPs entering Singapore are moderate from a regulatory standpoint — MAS CMS licensing is achievable — but very high from a competitive standpoint. The LP base already allocated to established names, the proprietary deal networks built over a decade, and Temasek's role as anchor LP in select commercial funds (Affinity III being the clearest example) create a structural moat that a new entrant cannot replicate quickly. [Chambers PE Guide Singapore 2025]
The clearest white space in Singapore PE is mid-market healthcare — well-funded interest but no dominant operator.
On deal size and sector focus, the seven leading firms cluster predictably — leaving one quadrant genuinely open.
- Temasek
- GIC
- CVC Capital
- Partners Group
- Hillhouse
- MBK Partners
- Affinity
- Quadria Capital
Mapping Singapore's leading PE firms on deal size (large buyout versus mid-market) and sector orientation (generalist versus specialist) reveals a predictable cluster at large generalist and a thinner set at mid-market specialist. Temasek and GIC sit in a category of their own — they operate across all quadrants simultaneously, which is one expression of sovereign permanent capital.
Among commercial GPs, CVC is unambiguously large-cap and generalist. Partners Group sits in large-cap territory but with increasing sector structure around infrastructure and healthcare. Hillhouse is large-cap and specialist — technology and consumer. MBK is large-cap and generalist with a Korea-heavy geographic bias. Affinity is the clearest mid-market generalist with Southeast Asian deal expertise. [Preqin Q4 2025]
The mid-market healthcare quadrant — sub-US$500m deal sizes, healthcare sector focus — is where Quadria Capital operates, but Quadria (US$3.4bn AUM) has not yet achieved the scale of the seven named leaders. [Dakota Rankings 2025] EY's 2026 Southeast Asia PE Pulse identifies healthcare as the sector where LP interest is highest relative to deployed capital — a gap that signals either an imminent large fund close in this space or continued fragmentation. [EY Southeast Asia PE Pulse 2026] The firm that closes a dedicated mid-market healthcare fund above US$3bn in the next 18 months takes a position that will be hard to dislodge.
Fund closes in 2024–2025 reveal which firms have LP conviction — and which are still proving their case.
A completed fund close is the clearest competitive signal in PE. Mid-raise gaps at Hillhouse and MBK are the data to watch.
The fund close record for 2024–2025 is the most legible competitive signal available in Singapore PE. Six significant fund events across the top seven firms reveal a bifurcated fundraising environment: sovereign vehicles and established commercial brands closed on or near target; newer or mid-cycle raises are running below target after extended periods in market.
GIC's Growth PE VII closed at US$12bn in March 2025 — the largest single PE vehicle closed from a Singapore-domiciled manager in the 18-month window. [PitchBook Q1 2026] CVC Asia VI at US$7.7bn (October 2025) and Affinity III at US$5.2bn (September 2025) both closed within normal fundraising timelines, with Affinity's close anchored by a 15% Temasek commitment. [Preqin Q4 2025] Partners Group PG Asia Buyout 2024 closed at US$4.5bn in November 2024, supported by GIC co-investment relationships that accelerated the timeline. [Preqin Q4 2025]
The contrast with Hillhouse Fund V is striking. The fund launched with a US$10bn target and had raised US$6bn as of April 2025 — a 40% shortfall after what Preqin characterises as more than 12 months in market. [Preqin Q4 2025] MBK Partners V shows a similar pattern: US$6bn first close in July 2025 against a US$9bn target, with the Singapore arm accounting for 25% of regional LP commitments. Both situations reflect LP selectivity more than firm-specific weakness, but they create a window for competitors to poach prospective LPs who are re-evaluating their allocations.
Three specific fights will determine who leads Singapore PE over the next 18–24 months.
The contests are named, the stakes are quantifiable, and the signals that would indicate a leadership shift are already visible.
The three battles below are not generic market dynamics. They are specific competitive contests with named firms, named stakes, and observable signals. Each will produce a clearer winner by Q4 2027 — and the outcome of all three together will determine the ranking of commercial GPs in Singapore for the following decade.
The healthcare mid-market fight is the most open — no dominant operator exists yet, and EY's 2026 PE Pulse identifies it as the sector where LP interest most exceeds deployed capital. [EY Southeast Asia PE Pulse 2026] The technology growth equity fight between Hillhouse and CVC is already visible in their fund strategies: Hillhouse's tech-specialist positioning against CVC's generalist scale. The outcome will be read in whether Hillhouse closes Fund V at or near its US$10bn target. [Preqin Q4 2025] The LP loyalty fight — who captures re-up commitments as the 2022–2023 denominator effect clears — is the least visible but structurally the most consequential. Firms with the strongest DPI track records and the cleanest exit narratives will win the next fundraising cycle before it formally opens.
Three scenarios for Singapore PE competitive leadership through 2027 — the base case favours the specialists.
The scenario that plays out depends on one variable more than any other: whether Southeast Asian deal flow accelerates or stalls.
Scenario probabilities are Ren's qualitative assessment based on the structural forces described above and the directional signals visible in current fundraising data. They are not derived from a quantitative model. The base case — specialist GPs with proprietary pipelines pulling ahead — reflects the trajectory already visible in fund close data: Affinity closing cleanly at US$5.2bn while Hillhouse Fund V remains in market with a large gap to target. [Preqin Q4 2025]
- Hillhouse Fund V closes above US$9bn by Q3 2026
- Three or more Singapore-managed healthcare or technology exits above US$1bn by end-2026
- MBK Partners V reaches final close at or near US$9bn target
- MAS introduces new regulatory incentives attracting US/Europe LP capital to Singapore-domiciled funds
- Affinity and CVC dominate Southeast Asian mid-market deal flow through Q4 2026
- Hillhouse Fund V closes at US$7–8bn — below target but viable
- Healthcare mid-market fund above US$2bn closes by Q1 2027, fragmenting that white space
- LP re-up cycle restarts in H2 2026 as denominator effect clears, favouring DPI leaders
- Hillhouse Fund V fails to reach US$7bn, forcing a restructured vehicle or target reduction
- MBK Partners V stalls at first close — LP re-ups suspended
- Southeast Asian deal volume contracts more than 20% in 2026 vs 2025
- A significant Singapore-managed PE portfolio company default creating reputational contagion
The bull case requires two conditions simultaneously: a regional deal flow acceleration driven by Southeast Asian GDP growth, and a material improvement in Asia public equity valuations that reopens IPO exit routes. Neither is impossible — Mordor Intelligence's APAC PE market outlook projects continued market growth through 2028 — but both conditions have been 'imminent' for multiple consecutive years without materialising at the scale the market expects. [Mordor Intelligence APAC PE] The bear case is not a collapse — it is a freeze: LP re-ups stall, Hillhouse and MBK fail to close their current vehicles at scale, and deal activity contracts to the sovereign institutions plus one or two anchor commercial GPs. That outcome would shrink the commercial GP tier significantly.
Key things to remember
About About this report
This report maps the named competitors controlling Singapore's private equity market, how each wins LP capital and deal flow, and where the competitive fights will be decided over the next 18–24 months.
Investors, founders, and analysts who need a sourced, specific picture of the Singapore PE competitive field without requiring additional research.
Ren synthesised data from MAS Annual Report 2025, Preqin Q4 2025 Asia Report, PitchBook Q1 2026 Asia-Pacific PE Monitor, EY Southeast Asia Private Equity Pulse (February 2026), and Chambers Global Practice Guide (Private Equity 2025, Singapore chapter).
Primary data runs to Q1 2026; fund close figures are as of April 2026. Some AUM estimates carry ±2% variance across Preqin and PitchBook and are flagged accordingly.
Sources Sources & Methodology
Research conducted 10 Apr 2026. All statistics carry inline citation markers.
Temasek Holdings total AUM — Preqin Q4 2025 — US$288bn total AUM, ~US$120bn Singapore-attributed PE vs PEI Global Investor 150 (2025) — references Temasek PE allocations at US$148bn. Preqin's figure of US$288bn total AUM is used as it aligns with Temasek's own reported S$389bn net portfolio (MAS 2025 context). The US$148bn figure from PEI appears to represent direct PE allocations only, not total AUM. Both figures are structurally consistent — this report uses total AUM for comparability across firms.
Singapore PE market total AUM — MAS Annual Report 2025 — US$285bn PE/VC AUM under MAS oversight vs Preqin / PitchBook estimates — US$250–300bn range cited. MAS 2025 figure of US$285bn is used as the authoritative number — it is a Tier 1 regulatory source. Preqin and PitchBook estimates are consistent with this range, adding confidence.
No public data is available on specific management fee or carried interest structures for any named Singapore PE firm. The 2%/20% industry standard is assumed but unverifiable from any cited source. All sections requiring fee data are omitted — not estimated.
LP satisfaction data, investor survey results, and named underperformance citations are absent from all available sources. No section attempts to synthesise LP sentiment without named public evidence.
Specific deal-level data for Quadria Capital, Affirma Capital, Northstar Group, and PAG's Singapore operations was not available in the research provided. These firms are referenced where named sources permit, but competitive profiles could not be built for them.
Hillhouse Fund V fundraising status (US$6bn raised vs US$10bn target) is sourced from Preqin Q4 2025 and may have changed by the date of this report. This figure should be verified against current Preqin Pro data before use in investment decisions.
Market share percentages for all firms carry a stated variance of ±2% (Preqin) to ±2–4% (PitchBook estimates). No single authoritative source publishes exact Singapore-attributed PE market share by manager. All figures in this report are estimates, rated MEDIUM confidence accordingly.
This report is produced for informational purposes only. It does not constitute financial, legal, or investment advice. All data is sourced from publicly available information as at the date of research. Renatus Ventures makes no representations as to the completeness or accuracy of third-party data.
